ArticleDiscover oncology2025

The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis.

Qiling Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.